Fresenius Medical Care AG & Co. (NYSE:FMS) Receives Average Recommendation of “Hold” from Analysts

Fresenius Medical Care AG & Co. (NYSE:FMS) has been given an average rating of “Hold” by the eleven analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $53.05.

Several research analysts recently issued reports on FMS shares. Zacks Investment Research downgraded shares of First Merchants from a “hold” rating to a “sell” rating in a research report on Monday, July 1st. Royal Bank of Canada reduced their price target on shares of from GBX 3,000 ($39.20) to GBX 2,900 ($37.89) and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Barclays reiterated a “hold” rating and set a $14.00 price target on shares of MACOM Technology Solutions in a research report on Thursday, June 20th. Commerzbank reiterated a “hold” rating and set a $54.00 price target on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, May 9th. Finally, DZ Bank reiterated a “neutral” rating on shares of Gerresheimer in a research report on Thursday, July 11th.

FMS traded down $0.61 during trading on Friday, reaching $37.77. 220,564 shares of the company’s stock were exchanged, compared to its average volume of 224,586. Fresenius Medical Care AG & Co. has a fifty-two week low of $30.99 and a fifty-two week high of $53.40. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.02 and a quick ratio of 0.79. The firm has a 50 day moving average of $38.55. The company has a market cap of $23.38 billion, a P/E ratio of 16.64, a P/E/G ratio of 2.70 and a beta of 1.43.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its earnings results on Thursday, May 2nd. The company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Fresenius Medical Care AG & Co. had a net margin of 11.94% and a return on equity of 10.27%. The company had revenue of $4.13 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the previous year, the company earned $0.91 EPS. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. Sell-side analysts anticipate that Fresenius Medical Care AG & Co. will post 2.4 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in FMS. Magellan Asset Management Ltd increased its stake in shares of Fresenius Medical Care AG & Co. by 52.3% in the 4th quarter. Magellan Asset Management Ltd now owns 1,433 shares of the company’s stock valued at $46,000 after acquiring an additional 492 shares during the last quarter. Hartwell J M Limited Partnership increased its stake in shares of Fresenius Medical Care AG & Co. by 4.4% in the 1st quarter. Hartwell J M Limited Partnership now owns 16,500 shares of the company’s stock valued at $669,000 after acquiring an additional 700 shares during the last quarter. Harvest Group Wealth Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. in the 1st quarter valued at about $29,000. NEXT Financial Group Inc bought a new stake in shares of Fresenius Medical Care AG & Co. in the 2nd quarter valued at about $29,000. Finally, Rehmann Capital Advisory Group increased its stake in shares of Fresenius Medical Care AG & Co. by 46.7% in the 1st quarter. Rehmann Capital Advisory Group now owns 2,565 shares of the company’s stock valued at $104,000 after acquiring an additional 817 shares during the last quarter. 1.46% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.